Guardant Health

@GuardantHealth

Revolutionizing detection, care, and treatment via Guardant360.

Silicon Valley
Vrijeme pridruživanja: lipanj 2012.

Tweetovi

Blokirali ste korisnika/cu @GuardantHealth

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @GuardantHealth

  1. 21. sij
    Prikaži ovu nit
    Poništi
  2. 21. sij

    Kumud’s leadership and his experience across the technology, cybersecurity, telecommunications and finance sectors will be a great asset as we scale up our data infrastructure and prepare for our next phase of growth.

    Prikaži ovu nit
    Poništi
  3. 21. sij

    We are thrilled to announce that Kalia has joined Guardant as our Chief Information Officer. Kumud will lead Guardant’s enterprise application, information technology, and security teams.

    Prikaži ovu nit
    Poništi
  4. 13. sij

    We are excited to work with to develop the Guardant360 companion diagnostic test for AMG 510, an investigational oral therapy that inhibits KRAS G12C mutant protein.

    Prikaži ovu nit
    Poništi
  5. 13. sij

    The potential to target KRAS G12C, a mutation that was once thought to be undruggable, represents a potentially major therapeutic advancement.

    Prikaži ovu nit
    Poništi
  6. 13. sij

    We’re excited to announce the COBRA study with to validate the clinical utility of our molecular residual disease assay as a diagnostic biomarker for selecting which patients with stage II colon cancer need adjuvant chemotherapy.

    Poništi
  7. 19. pro 2019.

    This is an important new development for Medicare patients with advanced cancer and for Guardant Health. Medicare will expand coverage for Guardant360 across the vast majority of solid tumor cancers. Read more:

    Poništi
  8. 13. pro 2019.

    New data presented at shows Guardant360 effectively guides precision oncology treatment in metastatic breast cancer patients.

    Poništi
  9. 11. pro 2019.

    New study shows only 40 percent of patients with metastatic colon cancer receive guideline-recommended biomarker testing:

    Poništi
  10. 18. stu 2019.

    We were honored to accept the Outstanding Product, Medical Device/Diagnostic Award at the 2019 Ceremony on behalf of . Thank you for recognizing our work.

    Poništi
  11. proslijedio/la je Tweet

    Patient and caregiver non-profit organisations are now invited to submit proposals to Initiatives in Lung Cancer Care (ILC2), a grant opportunity for projects that can improve quality of care and the patient experience. Learn more here

    Poništi
  12. 23. lis 2019.

    We are proud to initiate the ECLIPSE trial, a 10,000-patient, pivotal study for our LUNAR-2 blood test for colorectal cancer screening. Read more:

    Poništi
  13. 28. ruj 2019.

    Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy

    Poništi
  14. 9. srp 2019.

    2.1 million people are diagnosed w/ each year globally. Yesterday, we joined , and to announce the Alliance, to one day end the disease as a cause of death:

    Poništi
  15. 15. velj 2018.

    We're excited to see the Guardant360 assay designated for the FDA's Expedited Access Pathway as we prepare our submission to the FDA later this year.

    Poništi
  16. 15. stu 2017.

    Important new research from about the genomic heterogeneity of gastroesophageal adenocarcinoma.

    Poništi
  17. proslijedio/la je Tweet
    24. lis 2017.

    Excited to discuss early cancer detection and precision medicine at the  .

    Poništi
  18. 17. kol 2017.

    Congratulations to our cofounders and AmirAli Talasaz for making @FortuneMagazines's 40 under 40 list!

    Poništi
  19. proslijedio/la je Tweet
    20. srp 2017.

    . abstr titles are out! Excited to be presenting results from 30,000 pts examined w ctDNA!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·